These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 25768835)

  • 1. Time above 1500 copies: a viral load measure for assessing transmission risk of HIV-positive patients in care.
    Marks G; Gardner LI; Rose CE; Zinski A; Moore RD; Holman S; Rodriguez AE; Sullivan M; Giordano TP
    AIDS; 2015 May; 29(8):947-54. PubMed ID: 25768835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Time Spent with HIV Viral Load > 1500 Copies/mL Among Persons Engaged in Continuity HIV Care in an Urban Clinic in the United States, 2010-2015.
    Lesko CR; Lau B; Chander G; Moore RD
    AIDS Behav; 2018 Nov; 22(11):3443-3450. PubMed ID: 29541913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Time to viral load suppression in antiretroviral-naive and -experienced HIV-infected pregnant women on highly active antiretroviral therapy: implications for pregnant women presenting late in gestation.
    Aziz N; Sokoloff A; Kornak J; Leva NV; Mendiola ML; Levison J; Feakins C; Shannon M; Cohan D
    BJOG; 2013 Nov; 120(12):1534-47. PubMed ID: 23924192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Behavioral and clinical characteristics of persons receiving medical care for HIV infection - Medical Monitoring Project, United States, 2009.
    Blair JM; Fagan JL; Frazier EL; Do A; Bradley H; Valverde EE; McNaghten A; Beer L; Zhang S; Huang P; Mattson CL; Freedman MS; Johnson CH; Sanders CC; Spruit-McGoff KE; Heffelfinger JD; Skarbinski J;
    MMWR Suppl; 2014 Jun; 63(5):1-22. PubMed ID: 24941443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Time spent with HIV viral load above 1500 copies/ml among patients in HIV care, 2000-2014.
    Mendoza MCB; Gardner L; Armon C; Rose CE; Palella FJ; Novak RM; Tedaldi EM; Buchacz K;
    AIDS; 2018 Sep; 32(14):2033-2042. PubMed ID: 29958190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection.
    Hecht FM; Wang L; Collier A; Little S; Markowitz M; Margolick J; Kilby JM; Daar E; Conway B; Holte S;
    J Infect Dis; 2006 Sep; 194(6):725-33. PubMed ID: 16941337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High rates of baseline antiretroviral resistance among HIV-infected pregnant women in an HIV referral centre in Rio de Janeiro, Brazil.
    de Lourdes Teixeira M; Nafea S; Yeganeh N; Santos E; Gouvea MI; Joao E; Ceci L; Bressan C; Cruz ML; Sidi LC; Nielsen-Saines K
    Int J STD AIDS; 2015 Nov; 26(13):922-8. PubMed ID: 25504831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationships between HIV disease history and blood HIV-1 DNA load in perinatally infected adolescents and young adults: the ANRS-EP38-IMMIP study.
    Avettand-Fenoel V; Blanche S; Le Chenadec J; Scott-Algara D; Dollfus C; Viard JP; Bouallag N; Benmebarek Y; Rivière Y; Warszawski J; Rouzioux C; Buseyne F
    J Infect Dis; 2012 May; 205(10):1520-8. PubMed ID: 22427678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country.
    Kilaru KR; Kumar A; Sippy N; Carter AO; Roach TC
    HIV Med; 2006 Mar; 7(2):99-104. PubMed ID: 16420254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Value of HIV-1 viral load and CD4 lymphocyte count as determinants of progression to AIDS and survival].
    Romeu J; Balagué M; Ruiz L; Marfil S; Puig T; Arnó A; Veny A; Tural C; Sirera G; Clotet B
    Med Clin (Barc); 1998 Jun; 110(20):761-7. PubMed ID: 9666416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors associated with mother-to-child transmission of HIV-1 despite a maternal viral load <500 copies/ml at delivery: a case-control study nested in the French perinatal cohort (EPF-ANRS CO1).
    Tubiana R; Le Chenadec J; Rouzioux C; Mandelbrot L; Hamrene K; Dollfus C; Faye A; Delaugerre C; Blanche S; Warszawski J
    Clin Infect Dis; 2010 Feb; 50(4):585-96. PubMed ID: 20070234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence and predictors of virologic failure of antiretroviral triple-drug therapy in a community-based cohort.
    Paris D; Ledergerber B; Weber R; Jost J; Flepp M; Opravil M; Ruef C; Zimmerli S
    AIDS Res Hum Retroviruses; 1999 Dec; 15(18):1631-8. PubMed ID: 10606086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005.
    Hoen B; Cooper DA; Lampe FC; Perrin L; Clumeck N; Phillips AN; Goh LE; Lindback S; Sereni D; Gazzard B; Montaner J; Stellbrink HJ; Lazzarin A; Ponscarme D; Staszewski S; Mathiesen L; Smith D; Finlayson R; Weber R; Wegmann L; Janossy G; Kinloch-de Loes S;
    Clin Infect Dis; 2007 Aug; 45(3):381-90. PubMed ID: 17599319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retrospective analysis of suspending HAART in selected patients with controlled HIV replication.
    Jacobs B; Neil N; Aboulafia DM
    AIDS Patient Care STDS; 2005 Jul; 19(7):429-38. PubMed ID: 16053400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV-1 viral load and CD4 cell count in untreated children with vertically acquired asymptomatic or mild disease. Paediatric European Network for Treatment of AIDS (PENTA).
    AIDS; 1998 Mar; 12(4):F1-8. PubMed ID: 9520161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in viral load in people with virological failure who remain on the same HAART regimen.
    Cozzi-Lepri A; Phillips AN; Miller V; Katlama C; Ledergerber B; Vella S; Weber J; Bruun JN; Kirk O; Clotet B; Lundgrens JD
    Antivir Ther; 2003 Apr; 8(2):127-36. PubMed ID: 12741625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment exhaustion of highly active antiretroviral therapy (HAART) among individuals infected with HIV in the United Kingdom: multicentre cohort study.
    Sabin CA; Hill T; Lampe F; Matthias R; Bhagani S; Gilson R; Youle MS; Johnson MA; Fisher M; Scullard G; Easterbrook P; Gazzard B; Phillips AN;
    BMJ; 2005 Mar; 330(7493):695. PubMed ID: 15749728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of optimal viral suppression in patients switched to abacavir, lamivudine, and zidovudine: the Swiss HIV Cohort Study.
    Wolbers M; Opravil M; von Wyl V; Hirschel B; Furrer H; Cavassini M; Vernazza P; Bernasconi E; Battegay M; Yerly S; Günthard H; Bucher HC;
    AIDS; 2007 Oct; 21(16):2201-7. PubMed ID: 18090047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
    Landman R; Capitant C; Descamps D; Chazallon C; Peytavin G; Katlama C; Pialoux G; Bentata M; Brun-Vézinet F; Aboulker JP; Yéni P;
    J Antimicrob Chemother; 2009 Jul; 64(1):118-25. PubMed ID: 19420019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.
    McDermott AY; Terrin N; Wanke C; Skinner S; Tchetgen E; Shevitz AH
    Clin Infect Dis; 2005 Dec; 41(11):1662-70. PubMed ID: 16267741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.